Mark is Partner at MHA Baker Tilly International (BTI) (Ranked 9th largest in the world) specialising in Global Assurance, Financial Turnaround, Fashion & Cosmetics, Food Manufacture & Rural Industries. He leads the MHA UK ESG Audit & Advisory function. He is also engaged in food retail, and consumer industries and a multi award winning turnaround specialist
Mark trained at Macintyre Hudson and has remained with the firm, aside from a 15 year in industry role, building a national educational commercial organisation investing over £100m, Employing 1300 staff, working with 1000s of national and international businesses, leverage GDP in the south east and enable nearly 78,000 students to be educated. He pioneered the world class sustainability Eco Project at Betteshanger park (Kent) (being the longest building in Europe at that time) in a £30m Regeneration project. Mark has been in the C-Suite understanding the challenges facing national and international businesses.
Mark has delivered numerous turnarounds from financial services through to rural businesses, and national institutions.
Mark Charis Rural Policy Group – a think tank and advocate for sustainable rural policy across the United Kingdom linking food & farming to public health and environmental sustainability. The policy group launched its National Green Futures Report in 2021 to set the foundations for a rural-first approach to economic policy-making for a more sustainable UK plc. He is directly connected into Westminster and works on a non partisan basis with government to support the industries MHA Serves.
Mark has won numerous awards for his work including National Finance Director of the year 2007, Accounting for sustainability National award 2012 (ICEAW), National Business Finance Director 2014 (Finance Director) and the Institute of Directors (IOD) blue ribbon award for Governance and Finance excellence in 2018.
He is a Liveryman in the Worshipful Company of Fruiterers, a Member of the Guild of Freemen, A member of the livery of Chartered Accountants, IoD South East Lead for ESG and a member of the CBI’s South East Council.
Dylan Stoy, PSI’s Therapeutic Strategy Director, is dedicated to conducting and executing better clinical studies in PSI’s core therapeutic areas. Dylan has a wealth of experience in the oncology indication, with research interests in targeted drug delivery systems and optimizing the design and conduct of studies. Dylan has overseen clinical research from various roles including onsite research, design and trial conduct, clinical operations oversight, project management, and therapeutic strategy.
Dylan and his team are devoted to making participation for sites and patients in complex oncology studies more attainable and ensuring that both PSI’s teams and your study sites are highly trained and properly supported to handle any challenges your program might encounter. Dylan works closely with the core business units within PSI, overseeing research throughout the study lifecycle, providing strategic leadership to our teams and collaborators (both internally and externally), and delivering corporate-wide trainings to make PSI your full-service CRO for all things oncology.
Steve’s career in life science and healthcare spans more than 40 years. He has led the development and deployment of cloud-based solutions with a focus on driving more integrated approaches to patient-centric trial management. Today, he continues to leverage this deep experience to drive uMotif’s hypergrowth.
Steve was most recently Senior Vice President and General Manager of Oracle Health Sciences. Before that, Steve was at the forefront of advancing the adoption of electronic data capture and was the visionary behind the integrated clinical technology suite introduced by Phase Forward which was acquired by Oracle in 2010.
Steve has been named twice to the prestigious PharmaVoice 100 list. He recently served on the Board of Anju Software and currently sits on Prix Galien’s Digital Media and USA Digital Health Advisory boards. He also served a six-year term on CDISC’s Board.
As Director, Services Solutions at Suvoda, Amanda brings more than 10 years of experience working in client services. Prior to joining Suvoda, she held positions in science and consulting, operations, product development, and technical implementation with various technology vendors and CROs. With her extensive experience in decentralized trials, Amanda also serves as an eConsent expert at Suvoda. Amanda holds a master’s in Organizational Learning and Development from Suffolk University and a master’s in Health Sciences: Clinical Research Administration from George Washington University.
As the chief business officer, Peter is responsible for establishing and executing Frontier’s business development strategy which includes identifying target customers and managing the execution of the company’s sales strategy. Peter is also responsible for identifying opportunities for business growth and creating business partnerships, along with overseeing the activities and performance of the business development team.
Prior to joining Frontier, Peter started the Contract Manufacturing business for Pharmascience in Montreal. He built their US division for over 6 years and is credited for growing that new business vertical to over $200M. Pharmascience is a full service CMO specializing in development and manufacturing of complex oncology injectables.
Peter has over 15 years of experience in the Pharmaceutical industry. His experience spans from preclinical development, to API sales, to Generic injectable manufacturing. He began his career in preclinical safety pharmacology where he lead the business development unit for Huntington Life Sciences in Princeton NJ. Gradually, he worked his way into the Clinical Trial sector and took up a Director of Business Development role for AIT Biosciences in Indianapolis. He later spent 5 years in the API industry and began MSN Pharma’s first US office in Edison NJ.
He received his undergraduate degree from The University of California Irvine in Biology and a Masters Degree in Biotechnology from The University of Pennsylvania (UPENN).
Experienced Associate Director with a demonstrated history of working clinical research and education. Skilled in Analytical Skills, Biotechnology, Feasibility, Mentoring, Proposal Writing, and Leadership. Strong business development professional with a 2005 M.S. focused in Technical Communication from North Carolina State University.
SJ Sawhney is the co-founder of Canary Technologies, a leading solution provider that is modernizing the hotel tech stack with the first mobile web end-to-end Guest Management System, digitizing everything from post-booking through checkout. Prior to co-founding Canary, Sawhney led product and technology at Stayful, a booking platform for independent and boutique hotels founded by the former president of Hotels.com. Sawhney is a serial entrepreneur, having successfully founded multiple venture-backed technology companies over the prior decade. He is a graduate of Columbia University.
With 20 years of experience at Texaco Lubricants, Emma has taken on a variety of roles across the business, including within the customer service, sales, and marketing departments. Emma’s passion for the automotive sector has driven her career and has guided her as she has interacted with a large portfolio of clients, including automotive manufacturers, franchised dealer groups, power generation companies, and distributors.
Ed is a Data Strategy expert who has significant experience of designing and leading enterprise change programmes that deliver optimised customer experience. He has an in-depth understanding of data strategy, technology, data science, proposition development and governance . He has a proven track record of developing, implementing and running programmes within leading Insurance organisations.
Prior to joining CACI, Ed was Director of Data Governance at Dentsu Aegis Network where he led the global data governance and transformation function. Prior to this he led Data Strategy transformation for global brands including RBS Insurance, British Airways, HSBC and Public Health England.
Having begun his career at Texaco Lubricants as a development chemist in 1989, Eddy has a vast practical and technical knowledge of the formulation of engine oils. Specialising in offering technical and commercial input to the passenger car, commercial vehicle, and industrial sectors, he is on-hand to offer the expertise he has acquired from a career of working alongside a variety of global OEMs.
